Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
C2N Diagnostics and AbbVie announced that the Food and Drug Administration (FDA) has granted orphan drug designation for C2N-8E12 (ABBV-8E12) for the treatment of progressive supranuclear palsy (PSP). C2N-8E12 is a recombinant humanized antibody targeting the tau protein found in neurofibrillary tangles in the brain of patients with tauopathies such as PSP and Alzheimer’s disease (AD).
RELATED: Sarizotan Designated Orphan Drug for Neurologic Disorder
The Companies have also begun a Phase 1 randomized, double-blind, placebo-controlled, single ascending dose, multicenter study that will evaluate the safety, tolerability, and pharmacokinetics of C2N-8E12 in about 32 patients with PSP.
For more information visit C2NDiagnostics.com or AbbVie.com.
